REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX) has announced upcoming presentations of new interim data for ABBV-RGX-314 at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for treating wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other chronic retinal conditions.
The presentations will include:
- New results from a bilateral dosing study using subretinal delivery for wet AMD
- Data from a Phase 2 dose-escalation study evaluating suprachoroidal delivery for diabetic retinopathy
- Long-term follow-up results from the Phase I/IIa subretinal delivery program in wet AMD
These presentations will provide insights into the potential efficacy and safety of ABBV-RGX-314 across different delivery methods and retinal conditions.
REGENXBIO Inc. (Nasdaq: RGNX) ha annunciato prossime presentazioni di nuovi dati intermedi per ABBV-RGX-314 al meeting annuale dell'American Academy of Ophthalmology 2024. ABBV-RGX-314 è un terapeutico AAV investigativo sviluppato in collaborazione con AbbVie per il trattamento della degenerazione maculare senile umida (degenerazione maculare umida), della retinopatia diabetica e di altre condizioni retiniche croniche.
Le presentazioni includeranno:
- Nuovi risultati da uno studio di dosaggio bilaterale utilizzando la somministrazione subretinica per la degenerazione maculare umida
- Dati da uno studio di fase 2 di escalation della dose che valuta la somministrazione suprachoroidale per la retinopatia diabetica
- Risultati di follow-up a lungo termine dal programma di somministrazione subretinica di fase I/IIa nella degenerazione maculare umida
Queste presentazioni forniranno approfondimenti sull'efficacia e sulla sicurezza potenziale di ABBV-RGX-314 attraverso diversi metodi di somministrazione e condizioni retiniche.
REGENXBIO Inc. (Nasdaq: RGNX) ha anunciado próximas presentaciones de nuevos datos interinos para ABBV-RGX-314 en la reunión anual de la American Academy of Ophthalmology 2024. ABBV-RGX-314 es un terapéutico AAV en investigación que se desarrolla en colaboración con AbbVie para tratar la degeneración macular relacionada con la edad húmeda (degeneración macular húmeda), la retinopatía diabética y otras condiciones retinianas crónicas.
Las presentaciones incluirán:
- Nuevos resultados de un estudio de dosificación bilateral utilizando administración subretiniana para la degeneración macular húmeda
- Datos de un estudio de fase 2 de escalado de dosis que evalúa la administración suprachoroidal para la retinopatía diabética
- Resultados de seguimiento a largo plazo del programa de administración subretiniana de fase I/IIa en degeneración macular húmeda
Estas presentaciones proporcionarán información sobre la eficacia y la seguridad potencial de ABBV-RGX-314 en diferentes métodos de administración y condiciones retinianas.
REGENXBIO Inc. (Nasdaq: RGNX)는 2024년 미국 안과 학회에서 ABBV-RGX-314의 새로운 중간 데이터를 발표할 예정입니다. ABBV-RGX-314는 AbbVie와 협력하여 개발 중인 AAV 치료제로, 습성 연령 관련 황반변성 (습성 AMD), 당뇨병성 망막병증 및 기타 만성 망막 질환 치료를 목표로 하고 있습니다.
발표 내용은 다음과 같습니다:
- 습성 AMD에 대한 망막하 전달 방식을 사용한 양측 투여 연구의 새로운 결과
- 당뇨병성 망막병증을 위한 초혈관 전달 평가의 2상 용량 증가 연구의 데이터
- 습성 AMD의 망막하 전달 프로그램에서의 1/2a상 장기 추적 결과
이 발표는 다양한 전달 방법과 망막 상태에서 ABBV-RGX-314의 잠재적인 효능과 안전성에 대한 통찰력을 제공할 것입니다.
REGENXBIO Inc. (Nasdaq: RGNX) a annoncé des présentations à venir de nouvelles données intermédiaires pour ABBV-RGX-314 lors de la réunion annuelle de l'American Academy of Ophthalmology 2024. ABBV-RGX-314 est un thérapeutique AAV expérimental développé en collaboration avec AbbVie pour traiter la dégénérescence maculaire liée à l'âge humide (dégénérescence maculaire humide), la rétinopathie diabétique et d'autres affections rétiniennes chroniques.
Les présentations comprendront :
- Nouveaux résultats d'une étude de dosage bilatérale utilisant l'administration subrétinienne pour la dégénérescence maculaire humide
- Données d'une étude de phase 2 sur l'escalade des doses évaluant l'administration suprachoroïdale pour la rétinopathie diabétique
- Résultats de suivi à long terme du programme d'administration subrétinienne de phase I/IIa pour la dégénérescence maculaire humide
Ces présentations fourniront des informations sur l'efficacité et la sécurité potentielles d'ABBV-RGX-314 selon différentes méthodes d'administration et conditions rétiniennes.
REGENXBIO Inc. (Nasdaq: RGNX) hat bevorstehende Präsentationen neuer Zwischenwerte für ABBV-RGX-314 auf der Jahrestagung der American Academy of Ophthalmology 2024 angekündigt. ABBV-RGX-314 ist ein experimentelles AAV-Therapeutikum, das in Zusammenarbeit mit AbbVie zur Behandlung von feuchter altersbedingter Makuladegeneration (feuchte AMD), diabetischer Retinopathie und anderen chronischen retinalen Erkrankungen entwickelt wird.
Zu den Präsentationen gehören:
- Neue Ergebnisse aus einer bilateralen Dosierungsstudie mit subretinaler Verabreichung für feuchte AMD
- Daten aus einer Phase-2-Dosissteigerungsstudie zur Bewertung der suprachoroidalen Verabreichung bei diabetischer Retinopathie
- Langzeitnachverfolgungsergebnisse aus dem subretinalen Verabreichungsprogramm der Phase I/IIa bei feuchter AMD
Diese Präsentationen werden Einblicke in die potenzielle Wirksamkeit und Sicherheit von ABBV-RGX-314 über verschiedene Verabreichungsmethoden und Netzhauterkrankungen hinweg bieten.
- Presentation of new interim data for ABBV-RGX-314 at a major ophthalmology conference
- Ongoing collaboration with AbbVie for development of ABBV-RGX-314
- Multiple presentations covering different delivery methods and indications for ABBV-RGX-314
- None.
New data will be presented as follows:
Title: Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study (abstract 30080148)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Saturday, October 19, 2024, at 11:59 a.m. ET
Encore presentations will be presented as follows:
Title: A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR (abstract 30078795)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Monday, October 21, 2024, at 10:45 a.m. ET
Title: Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD (abstract 30079480)
Presenter: Philip P. Storey, M.D., Austin Retina Associates
Date/Time: Monday, October 21, 2024, at 12:45 p.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
Zolgensma® is a registered trademark of Novartis Gene Therapies.
Contacts:
Dana Cormack
Corporate Communications
DCORMACK@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024-annual-meeting-302280013.html
SOURCE REGENXBIO Inc.
FAQ
What is ABBV-RGX-314 and what conditions is it being developed to treat?
What new data will REGENXBIO (RGNX) present at the American Academy of Ophthalmology 2024 meeting?
When and where will REGENXBIO (RGNX) present the new ABBV-RGX-314 data in October 2024?
